Medpace Holdings (MEDP) traded lower today as the market continued to focus on elevated clinical-trial cancellations and what that implies for backlog durability and growth momentum in 2026. The pressure has been reinforced by recent analyst target cuts that highlighted cancellation risk and a choppier setup coming out of the company’s latest quarter.

In its most recent reporting cycle (results issued February 10, 2026), Medpace posted strong year-over-year growth but drew investor scrutiny around cancellations and the quality of the setup for 2026. Medpace’s annual report also underscores a structural issue for CROs: backlog is not fully protected if customers cancel or reduce scope, which can quickly change forward revenue visibility.

Following the post-earnings volatility, at least two Wall Street firms reduced price targets while citing higher-than-expected cancellations and a “less-clean” quarter, keeping attention on whether the 2026 outlook is de-risking fast enough to justify the stock’s premium valuation. With the stock still anchored near levels seen after the February drawdown, incremental selling can be triggered by any renewed caution on awards, backlog conversion, or cancellation trends.